Skip to main content
. 2016 May 21;7(27):41691–41702. doi: 10.18632/oncotarget.9541

Figure 4. EGFR inhibitor shows durable clinical response in a patient harboring MET exon 14 skipping.

Figure 4

(A) FISH indicated that a MET exon 14 skipping positive non-smoker harbored EGFR, HER2, and MET copy number gains; IHC showed that this patient's tumor was positive for MET expression; (B) CT scan of the thorax demonstrating mediastinal lymph nodes enlargement and a left lobe mass before and after treatment with oral Iressa daily; (C) Timeline of the patient with MET exon 14 skipping lung.